--- title: Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds nct_id: NCT06445699 overall_status: RECRUITING phase: NA sponsor: Army Medical University, China study_type: INTERVENTIONAL primary_condition: Photodynamic Therapy countries: China canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06445699.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06445699" ct_last_update_post_date: 2024-07-30 last_seen_at: "2026-05-12T06:36:50.885Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds **Official Title:** Investigation the Clinical Effectiveness of Combination Topical Aminolaevulinic Acid-Photodynamic Therapy With Hydrogel Dressing for Treatment Chronic Cutaneous Wounds **NCT ID:** [NCT06445699](https://clinicaltrials.gov/study/NCT06445699) ## Key Facts - **Status:** RECRUITING - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 69 - **Lead Sponsor:** Army Medical University, China - **Conditions:** Photodynamic Therapy - **Start Date:** 2023-01-01 - **Completion Date:** 2024-08 - **CT.gov Last Update:** 2024-07-30 ## Brief Summary 63 patients with chronic infectious wounds were enrolled in the controlled study. They were randomly divided into three groups equally. Group 1 (Grp.1): The patients received hydrogel dressing change at three days intervals. Group 2 (Grp.2): The patients received ALA-PDT treatment at ten days intervals for 4 sessions. Groups 3 (Grp.3): The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. The wound healing rate, total effective rate, patient satisfaction, adverse reaction, and recurrence were assessed in all groups. ## Detailed Description Randomly divide the enrolled patients into three groups for treatment by utilizing SAS software (SAS Institute, Cary, NC, U.S.A.). Initially, the wound pus and secretions were washed three times with a sterile saline solution. Subsequently, surgical instruments were employed to debride the wound, particularly the necrotic tissue, as well as any carrion and foreign bodies within the wound bed and cavity, with care being taken to avoid injury to nerves and blood vessels in the surrounding area. Grp.1 was covered with hydrogel dressing (PAUL HARTMANN AG, Germany) and replaced 2-3 times a week with topical mupirocin ointment three times a day. Grp.2 received photodynamic therapy only. Grp.3 accepted PDT, then coated with hydrogel dressing as mentioned above. The treatment protocol of PDT is described as follows: after thorough debridement, ALA (Shanghai Fudan-Zhang jiang Bio-Pharmaceutical Co. Ltd, China) in an oil-in-water emulsion was smeared on the wound. After covering with dark plastic film for 3h, the wounds were illuminated by a light-emitting diode (LED) red light (Shenzhen Lifotronic Technology Co., Ltd, China). After the operation, a cold ice compress can be used to relieve the swelling and pain. Then, the hydrogel was uniformly applied to the wound and its surroundings (Grp.3). Grp.2 and Grp.3 received PDT at an interval of ten days for 4 sessions. In all groups, treatment responses and adverse reactions were recorded. All patients received the treatment as mentioned above and then evaluated the clinical outcome. After the end of the treatment, all patients returned for follow up at weeks 2, 4, 8 and 12. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 70 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * 1\) patients with chronic wounds caused by trauma or surgery who failed to heal after traditional formal medical treatment at least over three months; * 2\) Patients with stable vital signs who had no systemic medical disease and did not take glucocorticoids, immunosuppressive agents, or anticoagulants during the entire treatment process; * 3\) Participants provided signed informed consent, were able to comply with the program, were willing to participate in follow-up, and were able to cooperate in the observation of adverse events and efficacy; * 4\) The diameter of the skin wound should not exceed 10 centimeters. Exclusion Criteria: * 1\) Patients are allergic to ALA; * 2\) Women with recent fertility, pregnancy or lactation plans; * 3\) Patients with deepening wounds or worsening infections; * 4\) Poor compliance leading to an inability to complete the treatment in its entirety; * 5\) Cutaneous ulcer caused by vascular disease, autoimmune diseases, metabolic diseases, local or metastatic malignant tumors. ``` ## Arms - **Group 1 (Grp.1)** (ACTIVE_COMPARATOR) — The patients received hydrogel dressing change at three days intervals - **Group 2 (Grp.2)** (EXPERIMENTAL) — The patients received ALA-PDT treatment at ten days intervals for 4 sessions. - **Group 3 (Grp.3)** (EXPERIMENTAL) — The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. ## Interventions - **Photodynamic therapy** (OTHER) — A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization. - **Hydrogel dressing** (OTHER) — Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain. ## Primary Outcomes - **Wound healing rate** _(time frame: Up to 12 weeks after the end of the treatment.)_ — Panoramic photographs of the wounds were taken by the same observer at each treatment and return visit using a digital camera, and the wound area was recorded using Image-Pro Plus 6.0 software. Wound size on the first day of treatment was considered to be 100%. The change in wound area size was compared to the initial before treatment and calculated as a percentage reduction. - **The total effectiveness rate** _(time frame: Up to 12 weeks after the end of the treatment.)_ — The evaluation criteria were as follows: 1) If the wound area is completely healed, treatment was considered "significantly effective" (SE); 2) if the wound area was at least 50% healed, treatment was considered "effective" (E); 3) If the wound area was healed 30 - 50%, the treatment is considered as "improved" (IMP); 4) If the wound area is healed less than 30%, it is considered as "ineffective" (INE). "The total effectiveness rate" (Et) was calculated from the equation as follows: Et = (NSE+NE)/Nt × 100% NSE = the number of patients belonging to the SE groups NE = the number of patients belonging to the E groups Nt = the total number of patients - **Patient satisfaction** _(time frame: Up to 12 weeks after the end of the treatment.)_ — Patients were surveyed about their level of satisfaction with the results after 12 weeks following the final course of treatment with the results as "satisfied," "somewhat satisfied," "somewhat dissatisfied," or "dissatisfied." ## Locations (1) - Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, Chongqing Municipality, China — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.department of dermatology, southwest hospital, third military medical university (army medical university)|chongqing|chongqing municipality|china` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT06445699.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT06445699* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*